市场调查报告书
商品编码
1417592
全球眼科黏弹性器材市场评估:依产品类型、成分、应用、最终用户、地区、机会、预测(2017-2031)Ophthalmic Viscoelastic Devices Market Assessment, By Product Type, By Composition, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球眼科黏弹性器材市场规模预计到2023年将达到30.1亿美元,到2031年将达到44.8亿美元,2023-2031年预测期间复合年增长率为5.1%。由于眼科疾病盛行率的增加、老年人口的增加以及眼科设备的进步等主要因素,全球眼科黏弹性设备市场正在呈现显着成长。此外,生活方式的改变、萤幕时间的增加以及慢性病盛行率的上升导致眼部疾病患者数量的增加,从而推动了对眼科黏弹性装置的需求。
由于白内障、青光眼、角膜移植和玻璃体视网膜手术等各种手术的需求不断增加,预计眼科黏弹性装置市场将显着成长。老年人群特别容易出现视力障碍,进一步增加了对眼科黏弹性装置的需求。此外,糖尿病、高血压等慢性病的流行也对市场产生影响,而这些疾病往往伴随眼部疾病。技术进步、支持医疗基础设施的政府政策以及医疗设备的可用性正在推动市场成长。然而,手术后眼压升高的风险以及替代疗法的存在等问题可能会阻碍市场扩张。
2023年4月,Bausch + Lomb Corporation宣布在美国市场推出两款黏弹性装置:StableVisc cohesive OVD和TotalVisc Viscoelastic System。这两种装置均含有透明质酸钠和山梨醇的混合物,与其他可用的眼科黏弹性装置相比,可提供强大的物理屏障并增强自由基清除能力。
屈光不正、白内障、糖尿病性视网膜病变、青光眼和老年黄斑部病变(AMD)等眼科疾病的盛行率日益增加,对全球眼科黏弹性装置(OVD)市场产生了重大影响。由于不健康的生活方式、营养不良和萤幕时间过长等因素,这些疾病呈现上升趋势。这些疾病的日益普及预计将推动对广泛用于眼科手术的眼科黏弹性装置的需求。根据世界卫生组织 2023 年 8 月的情况说明书,全球有 22 亿人患有近视或远视。其中,10亿人因远视力障碍而失明,其中9,400万人因白内障、8,840万人因屈光不正、800万人因老年黄斑部病变、770万人因青光眼和390万人因糖尿病视网膜病变而失明。老花眼影响 8.26 亿人,是损害近距离视力的主要疾病。
人口老化是导致眼科黏弹性装置需求不断增长的另一个重要面向。老年人更有可能患有影响眼睛的慢性疾病和眼科疾病。据世界卫生组织称,到2030年,世界上六分之一的人将超过60岁。60岁以上人口将从2020年的10亿增加到2030年的14亿。到2050年,地球上60岁以上的人口数量将翻倍,达到21亿人。预计到 2050 年,80 岁及以上的人口数量将翻两番,达到 4.26 亿。
预计在预测期内,黏性眼科黏弹性装置领域将在全球眼科黏弹性装置中占据主导地位。黏性眼科黏弹性装置被广泛使用,因为它们具有高黏度(增加手术环境稳定性)和高黏性(有利于手术切除)等优点。这可以稳定结构并允许对其占据的空间加压。白内障盛行率的增加和眼科黏弹性装置的技术进步是黏性眼科黏弹性装置领域占据主导地位的原因。市场公司正在扩大其产品组合,以获得该产品类别的竞争优势。
本报告研究分析了全球眼科黏弹性器材市场,提供市场规模和预测、市场动态、主要参与者现状和前景等。
Global ophthalmic viscoelastic devices market size was valued at USD 3.01 billion in 2023 and is expected to reach USD 4.48 billion in 2031, with a CAGR of 5.1% for the forecast period between 2023 and 2031F. The global market for ophthalmic viscoelastic devices is experiencing significant growth due to several key factors, such as the increasing prevalence of eye-related disorders, the growing elderly population, and advancements in ophthalmic devices. Additionally, lifestyle changes, prolonged screen time, and the rising incidence of chronic diseases contribute to more patients with eye disorders, driving the demand for ophthalmic viscoelastic devices.
The ophthalmic viscoelastic devices market is projected to grow substantially, driven by the increasing demand for various surgical procedures, including those related to cataracts, glaucoma, corneal transplantation, and vitreoretinal surgery. The geriatric population is particularly susceptible to vision impairment, further boosting the need for ophthalmic viscoelastic devices. Furthermore, the market is influenced by the prevalence of chronic conditions such as diabetes and hypertension, which are often associated with eye disorders. Technological advancements, government policies supporting healthcare infrastructure, and enhanced availability of medical devices are fueling the market growth. However, challenges such as the risk of a rise in ocular pressure after surgery and the presence of alternative therapies may impede market expansion.
In April 2023, Bausch + Lomb Corporation announced the launch of two viscoelastic devices, StableVisc cohesive ophthalmic viscosurgical device (OVD) and TotalVisc Viscoelastic System, in the United States market. Both the devices contain a mix of sodium hyaluronate and sorbitol, providing a strong physical barrier and delivering increased free radical scavenging capabilities compared to other available ophthalmic viscoelastic devices.
The increasing prevalence of ophthalmic disorders, such as refractive errors, cataracts, diabetic retinopathy, glaucoma, and age-related macular degeneration (AMD), significantly impacts the global ophthalmic viscoelastic devices (OVDs) market. These disorders are on the rise due to factors like unhealthy lifestyles, nutritional deficiency, and longer screen time. The increasing prevalence of these diseases is expected to drive the demand for ophthalmic viscoelastic devices, as these devices are extensively used in ophthalmic surgeries. A WHO factsheet from August 2023 states that 2.2 billion people worldwide suffer from near or far-sightedness. Out of which, 1 billion are affected by blindness from distance vision impairment, including 94 million people with cataracts, 88.4 million with refractive error, 8 million with age-related macular degeneration, 7.7 million with glaucoma, and 3.9 million with diabetic retinopathy. Presbyopia, which affects 826 million people, is the main condition that impairs close vision.
Another important aspect that has contributed significantly to the increased need for ophthalmic viscoelastic devices is the aging population. People who are older tend to have comorbid ailments such as chronic illnesses and ophthalmic disorders that affect their eyes. As per WHO, by 2030, one in six people in the world will be 60 years of age or older. By 2030, there will be 1.4 billion over-60s, compared to 1 billion in 2020. By 2050, there will be twice as many people 60 years or older on the planet, i.e., 2.1 billion people. It is projected that the population of 80 years of age or older will quadruple to 426 million by 2050.
The cohesive ophthalmic viscoelastic devices segment in global ophthalmic viscoelastic devices is expected to dominate during the forecast period. Cohesive ophthalmic viscoelastic devices are being used extensively as they offer advantages such as high viscosity, which increases the stability of the surgical environment, and high cohesion, which eases surgical removal. It stabilizes structures and enables pressurization of the space they occupy. The growing prevalence of cataracts and technological advancements in ophthalmic viscoelastic devices are reasons for the dominance of the cohesive ophthalmic viscoelastic devices segment. Market players are expanding their product portfolio to gain a competitive edge in this product category.
With high investment in research and development activities, technological advancements by key players, and advanced healthcare infrastructure in countries, like the United States and Canada, the region is expected to dominate the market with the highest value share. Supportive government initiatives for managing the growing number of ophthalmic surgeries are embracing the growth of the market in the region. High disposable income and preference for ophthalmic treatments of eye problems, along with the presence of key players, are contributing to the dominance of North America in the ophthalmic viscoelastic devices market.
Growth in healthcare infrastructure in developing countries and efforts to reduce the burden of ophthalmic disorders like integrated people-centered eye care (IPEC) by WHO is expected to set a positive trend for the market. Key market players focus on developing innovative products and expanding their market presence. In terms of regional growth, Asia-Pacific market is expected to experience a robust CAGR, driven by its sizable population, rising disposable income, and growing patient awareness of the need for eye care. In the future, surgeons might be able to carry out more intricate and accurate surgeries, and viscoelastic devices might be utilized to operate a wider range of ocular ailments.
The global ophthalmic viscoelastic devices market consists of market players like Bausch & Lomb Incorporated, Alcon Laboratories, Inc., Johnson & Johnson Surgical Vision Inc., and others, who are expanding their product offerings and giving their customers access to a wide range of cutting-edge and novel products.
For instance, In January 2022, Glaukos Corporation announced that it received 510(k) clearance from the United States Food and Drug Administration (FDA) for its viscoelastic device named 'iPRIME Viscodelivery System'. Glaukos is an ophthalmic medtech and pharmaceutical company dedicated to developing novel therapies for managing glaucoma, retinal diseases, and corneal disorders. iPRIME Viscodelivery System is a single-use, sterile, minimally-invasive device for delivering viscoelastic fluid during ophthalmic surgeries.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.